After 3 weeks treatment of gemcitabine (50 mg/kg, once per week), gemcitabine suppressed the growth of RETSAT-KO tumors with decreased luciferase strength (P = 0.0023 parental + Gem versus RETSAT-KO + Gem, Supplementary Fig. 1 J-M), lower tumor size and weight (P = 0.0017 parental + Gem versus RETSAT-KO + Gem, Fig. 2L-N), and prolonged survival time (P = 0.0045 RETSAT-KO versus parental after gemcitabine treatment, Fig. 2O). The gene discussed is GEM; the disease is neoplasm.